Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie recently updated its clinical study titled ‘A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088.’ The study aimed to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adult Western, Han-Chinese, and Japanese participants. It also assessed the drug-drug interaction between itraconazole and ABBV-1088 in Western participants, marking a significant step in understanding the drug’s potential.
The study tested ABBV-1088, an oral capsule, across various doses and in combination with itraconazole. The primary goal was to gather basic scientific data on the drug’s effects and interactions.
This was a randomized, triple-masked, interventional study with a parallel assignment model. The primary purpose was basic science, focusing on understanding the pharmacokinetics and safety profile of ABBV-1088.
The study began on August 28, 2024, but was terminated as of the last update on October 29, 2025. These dates are crucial as they indicate the study’s timeline and its premature conclusion.
The termination of this study could impact AbbVie’s stock performance and investor sentiment, as it may signal challenges in the drug’s development. Competitors in the pharmaceutical industry may view this as an opportunity to advance their own research in similar areas.
The study is no longer active, but further details can be accessed on the ClinicalTrials portal.